• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events.

作者信息

Chindhy Shahzad, Joshi Parag, Khera Amit, Ayers Colby R, Hedayati S Susan, Rohatgi Anand

出版信息

J Am Coll Cardiol. 2018 Aug 7;72(6):698-700. doi: 10.1016/j.jacc.2018.05.043.

DOI:10.1016/j.jacc.2018.05.043
PMID:30072004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6152844/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d7/6152844/703ef0e96908/nihms-1505717-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d7/6152844/703ef0e96908/nihms-1505717-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d7/6152844/703ef0e96908/nihms-1505717-f0001.jpg

相似文献

1
Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events.肾功能受损对胆固醇流出能力、高密度脂蛋白颗粒数量及心血管事件的影响。
J Am Coll Cardiol. 2018 Aug 7;72(6):698-700. doi: 10.1016/j.jacc.2018.05.043.
2
Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).胆固醇流出能力、高密度脂蛋白颗粒数量与心血管事件发生率：来自JUPITER试验（他汀类药物在预防中的应用依据：一项评估瑞舒伐他汀的干预试验）的分析
Circulation. 2017 Jun 20;135(25):2494-2504. doi: 10.1161/CIRCULATIONAHA.116.025678. Epub 2017 Apr 27.
3
Current Understanding of the Relationship of HDL Composition, Structure and Function to Their Cardioprotective Properties in Chronic Kidney Disease.目前对慢性肾脏病患者中高密度脂蛋白组成、结构和功能与心脏保护特性之间关系的理解。
Biomolecules. 2020 Sep 21;10(9):1348. doi: 10.3390/biom10091348.
4
Inflammation Alters Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOW-CKD.炎症改变了慢性肾脏病患者高密度脂蛋白胆固醇与心血管风险之间的关系：来自 KNOW-CKD 的结果。
J Am Heart Assoc. 2021 Aug 17;10(16):e021731. doi: 10.1161/JAHA.120.021731. Epub 2021 Aug 7.
5
HDL in CKD-The Devil Is in the Detail.慢性肾脏病患者的高密度脂蛋白胆固醇——细节决定成败。
J Am Soc Nephrol. 2018 May;29(5):1356-1371. doi: 10.1681/ASN.2017070798. Epub 2018 Feb 22.
6
Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14++CD16+ monocyte counts that predict cardiovascular events in chronic kidney disease.载脂蛋白 A-I 水平降低和高密度脂蛋白胆固醇水平降低与中间型 CD14++CD16+单核细胞计数升高相关，后者可预测慢性肾脏病患者的心血管事件。
Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2120-7. doi: 10.1161/ATVBAHA.114.304172. Epub 2014 Jul 24.
7
Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.慢性肾脏病中的残余心血管风险：高密度脂蛋白的作用
Arch Med Res. 2015 Jul;46(5):379-91. doi: 10.1016/j.arcmed.2015.05.009. Epub 2015 May 23.
8
Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: A cross-sectional study in chronic kidney disease patients.胆固醇外排能力与高密度脂蛋白中血浆脂蛋白水平的相关性：慢性肾脏病患者的横断面研究。
Atherosclerosis. 2018 Mar;270:102-109. doi: 10.1016/j.atherosclerosis.2018.01.037. Epub 2018 Feb 2.
9
Cardiovascular metabolic risk factors and glomerular filtration rate: a rural Chinese population study.心血管代谢危险因素与肾小球滤过率：一项中国农村人群研究
Lipids Health Dis. 2016 Oct 12;15(1):180. doi: 10.1186/s12944-016-0346-9.
10
HDL cholesterol efflux capacity and incident cardiovascular events.高密度脂蛋白胆固醇流出能力与心血管事件的发生
N Engl J Med. 2014 Dec 18;371(25):2383-93. doi: 10.1056/NEJMoa1409065. Epub 2014 Nov 18.

引用本文的文献

1
Reverse cholesterol transport: current assay methods, alterations with disease and response to therapeutic intervention.胆固醇逆向转运：当前的检测方法、疾病相关改变及对治疗干预的反应
Front Cardiovasc Med. 2025 Jul 10;12:1608384. doi: 10.3389/fcvm.2025.1608384. eCollection 2025.
2
High density lipoprotein particle size and function associate with new cardiovascular events in patients with chronic kidney disease.高密度脂蛋白颗粒大小和功能与慢性肾病患者新发心血管事件相关。
PLoS One. 2025 Apr 1;20(4):e0320803. doi: 10.1371/journal.pone.0320803. eCollection 2025.
3
Improvement in bilirubin influence on cholesterol efflux capacity evaluation using the immobilized liposome-bound gel beads method.

本文引用的文献

1
Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes.慢性肾脏病对循环和影像学心脏生物标志物与结局相关性的修饰作用。
J Am Heart Assoc. 2017 Jul 5;6(7):e005235. doi: 10.1161/JAHA.116.005235.
2
High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport.终末期肾病患者的高密度脂蛋白（HDL）颗粒在促进胆固醇逆转运方面存在缺陷。
Sci Rep. 2017 Feb 2;7:41481. doi: 10.1038/srep41481.
3
HDL Cholesterol Efflux Capacity and Cardiovascular Events in Patients With Chronic Kidney Disease.
固定化脂质体结合凝胶珠法评估胆红素对胆固醇流出能力的影响的改善。
Biosci Rep. 2023 Jun 28;43(6). doi: 10.1042/BSR20230393.
4
HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy.高密度脂蛋白功能与动脉粥样硬化：活性二羰基化合物作为有前途的治疗靶点。
Circ Res. 2023 May 26;132(11):1521-1545. doi: 10.1161/CIRCRESAHA.123.321563. Epub 2023 May 25.
5
Low concentrations of medium-sized HDL particles predict incident CVD in chronic kidney disease patients.小而密的中等密度脂蛋白颗粒浓度低可预测慢性肾脏病患者的心血管疾病事件。
J Lipid Res. 2023 Jun;64(6):100381. doi: 10.1016/j.jlr.2023.100381. Epub 2023 Apr 24.
6
Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis.胆固醇流出能力及其与不良心血管事件的关联：一项系统评价和荟萃分析。
Front Cardiovasc Med. 2021 Dec 13;8:774418. doi: 10.3389/fcvm.2021.774418. eCollection 2021.
7
Impact of Dietary Lipids on the Reverse Cholesterol Transport: What We Learned from Animal Studies.膳食脂质对胆固醇逆转运的影响：来自动物研究的启示。
Nutrients. 2021 Jul 30;13(8):2643. doi: 10.3390/nu13082643.
8
High-Density Lipoproteins in Kidney Disease.高密度脂蛋白在肾脏病中的作用
Int J Mol Sci. 2021 Jul 30;22(15):8201. doi: 10.3390/ijms22158201.
9
Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?高密度脂蛋白亚群：慢性肾脏病心血管疾病风险中的友或敌？
Biomedicines. 2021 May 16;9(5):554. doi: 10.3390/biomedicines9050554.
10
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.慢性肾脏病中的脂蛋白和脂肪酸：分子和代谢改变。
Nat Rev Nephrol. 2021 Aug;17(8):528-542. doi: 10.1038/s41581-021-00423-5. Epub 2021 May 10.
慢性肾脏病患者的高密度脂蛋白胆固醇流出能力与心血管事件
J Am Coll Cardiol. 2017 Jan 17;69(2):246-247. doi: 10.1016/j.jacc.2016.10.054.
4
HDL cholesterol efflux capacity and incident cardiovascular events.高密度脂蛋白胆固醇流出能力与心血管事件的发生
N Engl J Med. 2014 Dec 18;371(25):2383-93. doi: 10.1056/NEJMoa1409065. Epub 2014 Nov 18.
5
High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).高密度脂蛋白胆固醇和颗粒浓度、颈动脉粥样硬化和冠状动脉事件：MESA（动脉粥样硬化的多民族研究）。
J Am Coll Cardiol. 2012 Aug 7;60(6):508-16. doi: 10.1016/j.jacc.2012.03.060. Epub 2012 Jul 11.